BRD2 and cancer: Prechemotherapy levels of ovarian markers were similar in women exposed to cancer and matched normo-ovulatory women (stage 1 group) for AMH (2.2 (1.4) ng/mL in cancer vs. 2.3 (1.5) ng/mL in healthy women) and E2 (50.1 (24.3) pg/mL in cancer vs. 46.3 (22.4) pg/mL in healthy women), but FSH values were slightly lower in the cancer group (4.7 (2.1) IU/L in cancer vs. 5.6 (1.5) IU/L in the healthy women (stage 1 group), p = 0.007).